Client News

Abivax to be Added to Nasdaq Biotechnology Index

CARBIOS maintains its commitment to build the Longlaville plant and adjusts its timeline

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement

Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth

AFYREN awarded Silver Medal by EcoVadis for CSR performance, ranking in the top 8% worldwide

MRM Health Enters Strategic Collaboration with Oncode Institute and the Netherlands Cancer Institute to Accelerate Program on Microbiome-Based Therapies that Enhance Cancer Immunotherapy

Abivax Presents Third Quarter 2025 Financial Results

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada